Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi

Abstract In 2003 the Fondazione Italiana Linfomi (FIL) started a clinical research program for investigating initial treatment of frail elderly patients with diffuse large B-cell lymphoma (DLBCL) identified by Comprehensive Geriatric Assessment (CGA). From 2003 to 2006, 334 elderly patients underwent CGA assessment, and 99 patients were classified as frail. Frail patients had a median age of 78 years, stage III–IV disease in 62% and age-adjusted International Prognostic Index (aaIPI) of 2–3 in 53%. Treatment consisted of several different regimens according to physician discretion. After a median follow-up of 36 months, 5-year overall survival (OS) was 28%. In multivariate analysis, aaIPI 2–3 (p = 0.005) and the presence of respiratory comorbidity (p = 0.044) were the only factors that showed independent correlation with OS. Frail patients had a poorer outcome compared with fit patients also if they were treated with rituximab-containing combination chemotherapy (hazard ratio 2.37, 95% confidence interval 1.48–3.78; p < 0.001). CGA is a valid tool to prospectively identify frail subjects among elderly patients with DLBCL.

[1]  P. Mazza,et al.  Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi , 2012, Leukemia & lymphoma.

[2]  Scott E. Smith,et al.  A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. , 2012, Blood.

[3]  Scott E. Smith,et al.  Analysis of very elderly (≥80 years) non‐hodgkin lymphoma: impact of functional status and co‐morbidities on outcome , 2012, British journal of haematology.

[4]  Elias Campo,et al.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.

[5]  M. Sorror.  Comorbidities and hematopoietic cell transplantation outcomes. , 2010, Hematology. American Society of Hematology. Education Program.

[6]  J. Briones,et al.  Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  C. Gross,et al.  Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. , 2009, Leukemia research.

[8]  G. Rossi,et al.  A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy , 2009, Cancer.

[9]  N. Schmitz,et al.  CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2009, Blood.

[10]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[11]  M. Extermann,et al.  Comprehensive geriatric assessment for older patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Federico,et al.  Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma , 2007, Leukemia & lymphoma.

[13]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Gherlinzoni,et al.  Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[16]  C. Boccomini,et al.  The Influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL). , 2001, Clinical lymphoma.

[17]  E. Noordijk,et al.  Different age limits for elderly patients with indolent and aggressive non‐Hodgkin lymphoma and the role of relative survival with increasing age , 2000, Cancer.

[18]  L. Balducci,et al.  The application of the principles of geriatrics to the management of the older person with cancer. , 2000, Critical reviews in oncology/hematology.

[19]  M. Extermann,et al.  Management of the frail person with advanced cancer. , 2000, Critical reviews in oncology/hematology.

[20]  L. Balducci,et al.  Non-Hodgkin's Lymphoma in the Elderly. , 1996, Cancer control : journal of the Moffitt Cancer Center.

[21]  G. Lyman,et al.  Management of cancer in the aged. , 1996, Comprehensive therapy.

[22]  W Hop,et al.  Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Pfeiffer,et al.  Comprehensive geriatric assessment. , 1991, Southern medical journal.

[24]  R. Scott,et al.  Long-Term Results , 2001 .